---
title: "Title"
author: Serdar Balcı
format:
  revealjs:
    scrollable: true
  gfm:
    preview-mode: raw
lang: en
# editor: visual
---

![](./img-local/Hallmarks-of-Cancer-10.jpg)

# Hallmarks of Cancer-1

# Serdar BALCI, MD

![](./img-local/Hallmarks-of-Cancer-11.jpg)

![](./img-local/Hallmarks-of-Cancer-12.png)

![](./img-local/Hallmarks-of-Cancer-13.png)

![](./img-local/Hallmarks-of-Cancer-14.png)

__Cell\. 2000 Jan 7;100\(1\):57\-70\.__

![](./img-local/Hallmarks-of-Cancer-15.jpg)

![](./img-local/Hallmarks-of-Cancer-16.png)

<span style="color:#FFFFFF"> _Cell_ </span>  <span style="color:#FFFFFF"> 2011 144\, 646\-674DOI: \(10\.1016/j\.cell\.2011\.02\.013\) </span>

__Cell\. 2011 Mar 4;144\(5\):646\-74__

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc\.</span>  _[ Terms and Conditions](http://www.elsevier.com/termsandconditions)_

![](./img-local/Hallmarks-of-Cancer-17.jpg)

![](./img-local/Hallmarks-of-Cancer-18.png)

<span style="color:#FFFFFF"> _Cell_ </span>  <span style="color:#FFFFFF"> 2011 144\, 646\-674DOI: \(10\.1016/j\.cell\.2011\.02\.013\) </span>

__Cell\. 2011 Mar 4;144\(5\):646\-74__

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc\.</span>  _[ Terms and Conditions](http://www.elsevier.com/termsandconditions)_

![](./img-local/Hallmarks-of-Cancer-19.png)

__Cell\. 2000 Jan 7;100\(1\):57\-70\.__

![](./img-local/Hallmarks-of-Cancer-110.jpg)

![](./img-local/Hallmarks-of-Cancer-111.png)

<span style="color:#FFFFFF"> _Cell_ </span>  <span style="color:#FFFFFF"> 2011 144\, 646\-674DOI: \(10\.1016/j\.cell\.2011\.02\.013\) </span>

__Cell\. 2011 Mar 4;144\(5\):646\-74__

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc\.</span>  _[ Terms and Conditions](http://www.elsevier.com/termsandconditions)_

![](./img-local/Hallmarks-of-Cancer-112.png)

__Cell\. 2000 Jan 7;100\(1\):57\-70\.__

![](./img-local/Hallmarks-of-Cancer-113.jpg)

![](./img-local/Hallmarks-of-Cancer-114.png)

<span style="color:#FFFFFF"> _Cell_ </span>  <span style="color:#FFFFFF"> 2011 144\, 646\-674DOI: \(10\.1016/j\.cell\.2011\.02\.013\) </span>

__Cell\. 2011 Mar 4;144\(5\):646\-74__

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc\.</span>  _[ Terms and Conditions](http://www.elsevier.com/termsandconditions)_

![](./img-local/Hallmarks-of-Cancer-115.png)

__Cell\. 2000 Jan 7;100\(1\):57\-70\.__

![](./img-local/Hallmarks-of-Cancer-116.jpg)

![](./img-local/Hallmarks-of-Cancer-117.png)

<span style="color:#FFFFFF"> _Cell_ </span>  <span style="color:#FFFFFF"> 2011 144\, 646\-674DOI: \(10\.1016/j\.cell\.2011\.02\.013\) </span>

__Cell\. 2011 Mar 4;144\(5\):646\-74__

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc\.</span>  _[ Terms and Conditions](http://www.elsevier.com/termsandconditions)_

![](./img-local/Hallmarks-of-Cancer-118.jpg)

![](./img-local/Hallmarks-of-Cancer-119.png)

<span style="color:#FFFFFF"> _Cell_ </span>  <span style="color:#FFFFFF"> 2011 144\, 646\-674DOI: \(10\.1016/j\.cell\.2011\.02\.013\) </span>

__Cell\. 2011 Mar 4;144\(5\):646\-74__

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc\.</span>  _[ Terms and Conditions](http://www.elsevier.com/termsandconditions)_

# 

__http://www\.cellsignal\.com/common/content/content\.jsp?id=science\-pathways__

![](./img-local/Hallmarks-of-Cancer-120.png)

__Robbins Basic Pathology__

# Hallmarks of Cancer

__Self\-sufficiency in growth signals__

__Insensitivity to growth inhibitory signals__

__Evasion of cell death__

__Limitless replicative potential__

__Development of sustained angiogenesis__

__Ability to invade and metastasize__

__Genomic instability__

__Tumor\-promoting inflammation__

![](./img-local/Hallmarks-of-Cancer-121.jpg)

# SELF-SUFFICIENCY IN GROWTH SIGNALS

# Self-Sufficiency in Growth Signals

* __Physiologic Growth__
  * __The binding of a growth factor to its specific receptor on the cell membrane__
  * __Transient and limited activation of the growth factor receptor\, which in turn activates several signal\-transducing proteins on the inner leaflet of the plasma membrane__
  * __Transmission of the transduced signal across the cytosol to the nucleus by second messengers or a cascade of signal transduction molecules__
  * __Induction and activation of nuclear regulatory factors that initiate and regulate DNA transcription__
  * __Entry and progression of the cell into the cell cycle\, resulting ultimately in cell division__

![](./img-local/Hallmarks-of-Cancer-122.png)

![](./img-local/Hallmarks-of-Cancer-123.jpg)

![](./img-local/Hallmarks-of-Cancer-124.png)

![](./img-local/Hallmarks-of-Cancer-125.png)

![](./img-local/Hallmarks-of-Cancer-126.png)

![](./img-local/Hallmarks-of-Cancer-127.jpg)

![](./img-local/Hallmarks-of-Cancer-128.png)

![](./img-local/Hallmarks-of-Cancer-129.png)

![](./img-local/Hallmarks-of-Cancer-130.png)

![](./img-local/Hallmarks-of-Cancer-131.png)

![](./img-local/Hallmarks-of-Cancer-132.png)

![](./img-local/Hallmarks-of-Cancer-133.jpg)

__Robbins Basic Pathology__

![](./img-local/Hallmarks-of-Cancer-134.png)

__Robbins Basic Pathology__

![](./img-local/Hallmarks-of-Cancer-135.png)

![](./img-local/Hallmarks-of-Cancer-136.png)

__Robbins Basic Pathology__

![](./img-local/Hallmarks-of-Cancer-137.png)

__Robbins Basic Pathology__

# Growth Factors

* __Cancer cells synthesize the same growth factors to which they are responsive__
* __Glioblastomas__
  * __secrete platelet\-derived growth factor \(PDGF\)__
  * __express the PDGF receptor__
* __Sarcomas__
  * __Make transforming growth factor\-α \(TGF\-α\)__
  * __TGF\-α receptor__

* __Interaction with stroma__
  * __Tumor cells send signals to activate normal cells in the supporting stroma__
  * __Then the stromal cells produce growth factors that promote tumor growth__

# Growth Factor Receptors andNon-Receptor Tyrosine Kinases

__Mutant receptor proteins:__

__Deliver continuous mitogenic signals to cells__

__Even in the absence of the growth factor in the environment__

* __Overexpression of growth factor receptors__
  * __Hyperresponsive to levels of the growth factor that would not normally trigger proliferation__
* __ERBB1 \(EGF receptor\)__
  * __Overexpressed in 80% of squamous cell carcinomas of the lung__
  * __50% or more of glioblastomas__
  * __80% to 100% of epithelial tumors of the head and neck__

* __HER2/NEU \(ERBB2\)__
  * __Amplified in 25% to 30% of breast cancers__
  * __Adenocarcinomas of the lung\, ovary\, and salivary glands__
  * __Sensitive to the mitogenic effects of small amounts of growth factors__
  * __A high level of HER2/NEU protein in breast cancer cells is a poor prognosis__
  * __Anti\-HER2/NEU antibodies used in breast cancer treatment__

# Downstream Signal-Transducing Proteins

* __They receive signal from receptors__
* __Carry signal to nucleus via__
  * __second messengers__
  * __cascade of phosphorylation__
* __If there is an autonomy in these signals there is continuous signal to nucleus__
* __RAS__
* __ABL__

# RAS protein

* __Most commonly mutated proto\-oncogene in human tumors__
* __30% of all tumors contain RAS mutation__
* __More common in colon and pancreas carcinoma__
* __G protein__
  * __Phosphorylation via GTP__

![](./img-local/Hallmarks-of-Cancer-138.png)

# RAS

* __Normally__
  * __active when bound to GTP__
  * __Deactivated by GTPase__
  * __GTPase\-activating proteins \(GAPs\)__
* __When mutated__
  * __ cannot dephosphorylate__
  * __Remains active__

__Robbins Basic Pathology__

![](./img-local/Hallmarks-of-Cancer-139.png)

# GAPs

* __GTPase\-activating protein__
* __Neurofibromin\-1 \(NF\-1\)__
  * __loss\-of\-function mutation__
  * __activation of RAS__
  * __Neurofibromatosis develops__

__Robbins Basic Pathology__

![](./img-local/Hallmarks-of-Cancer-140.png)

# RAF/ERK/MAP kinase pathway

__Active in 60% of melanomas__

__BRAF mutation seen in papillary thyroid carcinomas__

__Robbins Basic Pathology__

# ABL

* __Non\-receptor\-associated\-tyrosine kinase__
* __Chronic Myelogenous Leukemia__
  * __ABL translocates from Chr9 to Chr22__
  * __Fuses with BCR__
  * __Continuous activation__
  * __Also activates RAS pathway__
* __Targeted therapy is present__
  * __BCR\-ABL kinase inhibitor \(Gleevec\)__

![](./img-local/Hallmarks-of-Cancer-141.png)

__Robbins and Cotran’s Pathological Basis of Diseases__

# Nuclear Transcription Factors

* __MYC\, MYB\, JUN\, FOS\, and REL oncogenes__
  * __Regulate the expression of growth\-promoting genes\, such as cyclins__

# MYC

* __Activate growth\-promoting genes cyclin\-dependent kinases \(CDKs\)__
* __Inhibit CDK inhibitors \(CDKIs\)__
* __Upregulating genes that promote aerobic glycolysis \(Warburg effect\)__
* __İncreased utilization of glutamine__
* __Translocation__
  * __t\(8;14\) Burkitt lymphoma__
* __Amplification__
  * __Breast\, colon\, lung__
  * __Neuroblastomas\, Small cell cancers of lung \(NMYC\, LMYC\)__

![](./img-local/Hallmarks-of-Cancer-142.png)

__Robbins and Cotran’s Pathological Basis of Diseases__

![](./img-local/Hallmarks-of-Cancer-143.png)

__Robbins and Cotran’s Pathological Basis of Diseases__

![](./img-local/Hallmarks-of-Cancer-144.png)

__Robbins and Cotran’s Pathological Basis of Diseases__

# Cyclins and Cyclin-Dependent Kinases

* __Checkpoints__
* __G0 → G1__
* __G1 → S__
  * __Restriction point__
  * __Rate\-limiting step__

__Checkpoints to prevent proliferation of abnormal DNA__

![](./img-local/Hallmarks-of-Cancer-145.png)

__Inhibit__

__tumor growth__

__Activate tumor growth__

__Robbins Basic Pathology__

* __Increasing expression of cyclin D or CDK4 is common in neoplasia__
* __Cyclin D__
  * __breast\, esophagus\, liver\, and a subset of lymphomas and plasma cell tumors__
* __CDK4__
  * __melanomas\, sarcomas\, and glioblastomas\. __

* __CDKI__
  * __disabled by mutation or gene silencing in many human malignancies__
  * __Germline mutations of CDKN2A__
    * __25% of melanoma\-prone__
  * __Somatically acquired deletion or inactivation of CDKN2A__

![](./img-local/Hallmarks-of-Cancer-146.png)

__Robbins Basic Pathology__

# Homework

__Rous sarcoma virus__

![](./img-local/Hallmarks-of-Cancer-147.jpg)

# INSENSITIVITY TO GROWTH INHIBITORY SIGNALS

__Tumor Supressor Genes__

# RB Gene: Governor of the Cell Cycle

* __13q14__
* __Retinoblastoma occurs as a similar disease both in sporadic and familial forms__
* __Familial disease is Autosomal Dominant trait__
* __RB gene homozygous loss in__
  * __breast cancer\, small cell cancer of the lung\, and bladder cancer__
* __Patients with retinoblastoma have increased risk of__
  * __Osteosarcoma and soft tissue sarcomas__

# Retinoblastoma

![](./img-local/Hallmarks-of-Cancer-148.jpg)

![](./img-local/Hallmarks-of-Cancer-149.jpg)

![](./img-local/Hallmarks-of-Cancer-150.jpg)

![](./img-local/Hallmarks-of-Cancer-151.jpg)

__Figure 2\, from Pediatr Radiol\. Jun 2012; 42\(6\): 738–749\. PMCID: PMC3530407__

![](./img-local/Hallmarks-of-Cancer-152.jpg)

__Figure 7\.4b __  _ The Biology of Cancer_  __ \(© Garland Science 2007\)__

# Knudson two-hit hypothesis

![](./img-local/Hallmarks-of-Cancer-153.png)

__Robbins Basic Pathology__

![](./img-local/Hallmarks-of-Cancer-154.png)

__Robbins Basic Pathology__

# Does a cell become neoplastic when one Rb gene is mutated?

__No__

__Tumor Suppressor Genes require loss of function of both alleles to become neoplastic__

__Which mechanisms cause loss of function in a gene?__

__Does a cell become neoplastic when one allele of proto\-oncogene is mutated?__

![](./img-local/Hallmarks-of-Cancer-155.png)

__Robbins Basic Pathology__

![](./img-local/Hallmarks-of-Cancer-156.png)

__cyclin E transcription__

__Robbins Basic Pathology__

![](./img-local/Hallmarks-of-Cancer-157.png)

__HPV E7 protein mimics here__

__cyclin E transcription__

__Robbins Basic Pathology__

![](./img-local/Hallmarks-of-Cancer-158.png)

![](./img-local/Hallmarks-of-Cancer-159.png)

![](./img-local/Hallmarks-of-Cancer-160.png)

# TP53 GeneGuardian of the Genome

* __Quiescence__
  * __Activation of temporary cell cycle arrest__
* __Senescence__
  * __Induction of permanent cell cycle arrest__
* __Apoptosis__
  * __Triggering of programmed cell death__

__Rb “senses” external signals\, p53 monitors internal stress__

# p53 is activated by

__Anoxia__

__Inappropriate oncoprotein activity__

__Damage to the integrity of DNA__

__p53 is a DNA damage response protein__

# p53

* __Normally__
  * __p53 has a short half\-life__
  * __After 20 minutes associates with MDM2 and destructed__
* __When cell is stressed__
  * __Protein kinases are activated__
    * __ATM \(ataxia telangiectasia mutated\)__
  * __Make post transcriptional modifications in p53__
  * __p53 is released from MDM2__
  * __p53 activity continues__
* __After repair__
  * __p53 induces MDM2 expression and p53 levels decrease to normal\, cell cycle continues__

![](./img-local/Hallmarks-of-Cancer-161.png)

__Robbins Basic Pathology__

# p53-mediated cell cycle arrest

__p53 induces transcription of CDKI gene CDKN1A \(p21\)__

__p21 protein inhibits cyclin–CDK complexes__

__Prevents phosphorylation of Rb__

__Arresting cells in the G1 phase__

__Time to repair DNA damage__

# p53-induced senescence

__Involve global chromatin changes__

__Drastically and permanently alter gene expression__

__Permanent cell cycle arrest__

# p53-induced apoptosis

__Irreversible DNA damage__

__pro\-apoptotic genes such as BAX and PUMA__

# p53

* __70% of human cancers have a biallelic loss in p53__
* __Others have defects in genes upstream or downstream of TP53__
* __p53 is inhibited by oncogenic DNA viruses__
  * __Hepatitis B virus__
  * __possibly EBV__

# Li-Fraumeni syndrome

__Inherit a mutant TP53 allele__

__25x more cancer by age 50__

__Sarcomas\, breast cancer\, leukemia\, brain tumors\, carcinomas of the adrenal cortex__

__Younger age__

__Multiple primary tumors__

# Transforming Growth Factor-β Pathway

* __Potent inhibitor of proliferation__
* __TGF\-β receptors I and II__
  * __Activate with dimerization__
* __Growth\-suppressing activity__
  * __Transcriptional activation of CDKIs__
* __Repression of growth\-promoting genes __
  * __MYC\, CDK2\, CDK4__
  * __Encoding cyclins A and E__
* __SMAD molecules__
  * __Transduce antiproliferative signals from the receptor to the nucleus__
* __TGF\-β signaling activates epithelial\-to\-mesenchymal transition \(EMT\)__

![](./img-local/Hallmarks-of-Cancer-162.jpg)

__Figure 5\.21 __  _ The Biology of Cancer_  __ \(© Garland Science 2007\)__

# Transforming Growth Factor-β Pathway Alterations

* __Mutations in__
  * __Type II TGF\-β receptor__
    * __colon\, stomach\, and endometrium cancers__
  * __SMAD molecules__
    * __SMAD4 in pancreatic cancers__
* __100% of pancreatic cancers and 83% of colon cancers\, at least one component of the TGF\-β pathway is mutated__

![](./img-local/Hallmarks-of-Cancer-163.jpg)

__Figure 6\.29d __  _ The Biology of Cancer_  __ \(© Garland Science 2007\)__

# Contact Inhibition

* __Nontransformed cells are grown in culture__
  * __Proliferate until confluent monolayers are generated__
  * __Cell–cell contacts formed in these monolayers suppress further cell proliferation__
* __In cancer cells__
  * __No contact inhibition__
  * __Proliferate and pile on top of one another__

![](./img-local/Hallmarks-of-Cancer-164.png)

__Figure 3\.7 from The Biology Of Cancer \(2007\) \- Weinberg__

![](./img-local/Hallmarks-of-Cancer-165.jpg)

__Figure 3\.7a __  _ The Biology of Cancer_  __ \(© Garland Science 2007\)__

![](./img-local/Hallmarks-of-Cancer-166.jpg)

__Figure 3\.12 __  _ The Biology of Cancer_  __ \(© Garland Science 2007\)__

![](./img-local/Hallmarks-of-Cancer-167.png)

__Figure 3\.7 from The Biology Of Cancer \(2007\) \- Weinberg__

# E-cadherin

* __E\-cadherin mediates cell–cell contact in epithelial layers__
* __Tumor suppressor gene NF2 \(neurofibromin\-2\, merlin\)\, facilitates E\-cadherin mediated contact inhibition__
* __Homozygous loss of NF2 → neural tumors__
  * __Neurofibromatosis__
* __E\-cadherin is also regulated by APC \(adenomatous polyposis coli gene\)__

__No APC is present__

__β\-Catenin is active independent of WNT status__

__WNT signal inhibits APC__

__β\-Catenin enters nucleus__

__APC is active__

__β\-Catenin is dectructed__

![](./img-local/Hallmarks-of-Cancer-168.png)

__Robbins Basic Pathology__

__No APC is present__

__β\-Catenin is active independent of WNT status__

__WNT signal inhibits APC__

__β\-Catenin enters nucleus__

__APC is active__

__β\-Catenin is dectructed__

![](./img-local/Hallmarks-of-Cancer-169.png)

![](./img-local/Hallmarks-of-Cancer-170.png)

![](./img-local/Hallmarks-of-Cancer-171.png)

![](./img-local/Hallmarks-of-Cancer-172.png)

![](./img-local/Hallmarks-of-Cancer-173.png)

![](./img-local/Hallmarks-of-Cancer-174.png)

![](./img-local/Hallmarks-of-Cancer-175.png)

![](./img-local/Hallmarks-of-Cancer-176.jpg)

![](./img-local/Hallmarks-of-Cancer-177.png)

![](./img-local/Hallmarks-of-Cancer-178.png)

![](./img-local/Hallmarks-of-Cancer-179.png)

![](./img-local/Hallmarks-of-Cancer-180.png)

![](./img-local/Hallmarks-of-Cancer-181.png)

![](./img-local/Hallmarks-of-Cancer-182.png)

![](./img-local/Hallmarks-of-Cancer-183.png)

![](./img-local/Hallmarks-of-Cancer-184.png)

__Robbins Basic Pathology__

__β\-Catenin is active in the nucleus__

![](./img-local/Hallmarks-of-Cancer-185.png)

__cyclin D1 and MYC transcribed for proliferation__

__TWIST and SLUG are expressed__

__They repress E\-cadherin expression__

__Reduce contact inhibition__

__Robbins Basic Pathology__

# Adenomatous Polyposis Coli

* __APC is a tumor suppressor gene__
* __With one mutant allele__
  * __Hundreds to thousands of adenomatous polyps in the colon__
  * __By age 20s__
* __When other allele also mutated__
  * __Malignant transformation__
* __APC mutations are seen in 70% to 80% of sporadic colon cancers__
* __Colonic cancers with normal APC genes have activating mutations of β\-catenin__
  * __Refractory to the degrading action of APC__

![](./img-local/Hallmarks-of-Cancer-186.jpg)

__Figure 7\.22 __  _ The Biology of Cancer_  __ \(© Garland Science 2007\)__

![](./img-local/Hallmarks-of-Cancer-187.jpg)

__Figure 7\.24a __  _ The Biology of Cancer_  __ \(© Garland Science 2007\)__

